- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
The post MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 appeared first on MiNK Therapeutics.
The post MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia appeared first on MiNK Therapeutics.
The post MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025 appeared first on MiNK Therapeutics.
The post MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress appeared first on MiNK Therapeutics.
The post MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer appeared first on MiNK Therapeutics.
MiNK Therapeutics, Inc. today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting The post First-in-Kind Allo-iNKT Combination Data in 2L Gastric Cancer at AACR IO appeared first on MiNK Therapeutics.
Initial trial suggests invariant natural killer cell therapy improves survival The post New cell therapy shows promise with ARDS patients appeared first on MiNK Therapeutics.
AgenT-797 (MiNK Therapeutics), an allogeneic off-the-shelf invariant natural killer T-cell therapy was well-tolerated and improved survival inpatients with COVID-19-associated acute respiratory distress syndrome (ARDS) in addition to mechanical ventilation or ECMO. The post Terese Hammond, MD, on Promising Data With iNKT Cells in COVID-associated ARDS appeared first on MiNK Therapeutics.
The allogeneic off-the-shelf invariant natural killer T-cell (iNKT) therapy, agenT-797 (MiNK Therapeutics), was well-tolerated and improved survival in patients with COVID-19-associated acute respiratory distress syndrome (ARDS) in addition to mechanical ventilation or ECMO. The post Terese Hammond, MD, on Investigating iNKT Cells in COVID-Associated ARDS appeared first on MiNK Therapeutics.
MiNK Therapeutics, based in Lexington, believes its new cell therapy program could eventually replace chemotherapy with a less invasive treatment. The post Lexington-based company reports promising results in trials for cancer-treating cell therapy appeared first on MiNK Therapeutics.